Abstract

PurposeWe conducted a retrospective study to evaluate the intraocular pressure (IOP) lowering effect, the success rates, and the risk of bleeding events of patients receiving an iStent inject combined with phacoemulsification under anticoagulation therapy compared with a matched control group.MethodsIn this retrospective study, sixty-four eyes underwent an iStent inject implantation combined with phacoemulsification at two centers. Thirty-two eyes received surgery while under anticoagulation therapy, and another thirty-two eyes served as a control group matched for visual acuity, IOP, and medication score. Success was defined as criteria A and B (IOP < 18/21 mmHg, > 20% IOP reduction, no resurgery) and criteria C (IOP ≤ 15 mmHg, IOP reduction ≥ 40%, no resurgery). The clinical goal of the study was to determine the difference between the study and control groups with respect to IOP, medication score, and the frequency of intraoperative and postoperative bleeding events.ResultsAfter a mean follow-up time of 1 year, the IOP lowered 28% from 20.1 ± 4.8 to 14.5 ± 3.7 mmHg in the group of 64 eyes. The medication score lowered 38% from 2.1 ± 1.1 to 1.3 ± 1.2. The two groups with and without anticoagulant agents did not significantly differ in postoperative IOP, medication score, success rates, or number of bleeding events.ConclusionWe conclude that in cataract surgery combined with the iStent inject a discontinuation of anticoagulant agents might not be necessary. It might be a good option in glaucoma surgery when anticoagulation treatment should not be interrupted and the target pressure is not very low.

Highlights

  • Glaucoma is a disease of the elder population where anticoagulant agents are used frequently

  • Little is known about the complication rate of performing minimally invasive glaucoma surgery (MIGS) under anticoagulation therapy

  • We found 147 eyes with open-angle or exfoliation glaucoma undergoing an iStent inject implantation combined with phacoemulsification in two centers (Cologne, Düsseldorf)

Read more

Summary

Introduction

Glaucoma is a disease of the elder population where anticoagulant agents are used frequently. While it is generally accepted that intraocular bleeding after standard phacoemulsification cataract surgery does not justify the withdrawal of anticoagulant agents, Little is known about the complication rate of performing minimally invasive glaucoma surgery (MIGS) under anticoagulation therapy. Procedures with minimal angle trauma and significant efficacy in lowering intraocular pressure (IOP) are required. The iStent inject (Glaukos Corp., Laguna Hills, CA, USA) might be a minimally invasive option and decrease the risk of intraocular bleeding. We conducted a retrospective study to evaluate the IOP-lowering effect, the success rates, and the bleeding risk of patients receiving an iStent inject under anticoagulation therapy as compared with a matched control group

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call